NCT05052515Completed
The Effects of Dihydromiricetin on MASLD
The Effects of Natural Extract With Dihydromiricetin on MASLD Patients
Source: ClinicalTrials.gov · Last updated 21 May 2025
Brief summary (registry, in English)
The global wave of obesity has affected dramatically the incidence of non-alcoholic fatty liver disease (NAFLD) making it the leading cause of liver disease in the western world. NAFLD is considered the hepatic manifestation of metabolic syndrome and is strongly associated with type II diabetes, sleep apnea and cardiovascular disease. Although cardiovascular disease is the leading cause of death in patients with NAFLD, a subset of patients who meet the histological criteria for steatohepatitis have the highest risk for liver-related morbidity and mortality. Reviewing literature, it appears that several pathophysiologic mechanisms related to metabolism, inflammation and fibrosis are deregulated in NAFLD, whereas dihydromiricetin natural extracts have been suggested to exhibit antioxidant activity. In contrast to Vitamin E, which has been studied as an agent for non-diabetic patients with NAFLD, epidemiological and/or clinical data for the use of dihydromiricetin natural extracts or their combination in NAFLD are limited.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 55 (actual)
- First submitted
- 13 Sept 2021
- Start date
- 1 Nov 2021
- Primary completion date
- 30 Jun 2023
- Lead sponsor
- University of Athens
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT05052515
What you commit to
- Study type: Interventional
- Participants enrolled: 55
- From 1 Nov 2021 to the primary completion date, 30 Jun 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of a potentially hepatotoxic drug
Other illness
- Detection of hepatitis B virus (HBsAg) surface antigen or Hepatitis C virus antibodies (anti-HCV) or HIV antibodies
- The coexistence of α systemic disease with potentially hepatic involvement
Other
- Alcohol consumption \> 210 or \> 140 grams per week for men or women, respectively
Who the study is looking for
- Alanine aminotransferase (ALT) higher than the upper limit of normal with or without elevated γ-glutamyl transpeptidase (γGT)
- Hepatic steatosis-indicating findings on ultrasound and / or liver biopsy
- BMI 20-45 Kg/m2
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| General Hospital of Athens "Laiko" Coordinator of this site? Confirm its status | Athens | Greece | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.